Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Trial details
- Registry ID
- NCT06799247
- Drugs studied
- Decartes-08
TrialRedline tracks 6 clinical trials sponsored by Cartesian Therapeutics: 1 Phase 3, 5 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisNCT06799247 | Decartes-08 | Active not recruiting | 2026-12-30Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Descartes-08 in Autoantibody MyositisNCT07391605 | Descartes-08 | Recruiting | 2027-11Estimated |
| Descartes-08 for Patients With Systemic Lupus ErythematosusNCT06038474 | Descartes-08 | Active not recruiting | 2026-12-01Estimated |
| Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)NCT04146051 | Descartes-08 | Active not recruiting | 2026-01-05Actual |
| Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyNCT04436029 | Descartes 11 | Completed | 2022-02-18Actual |
| Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyNCT04816526 | Descartes 08 | Terminated | 2022-08-04Actual |
Names as written in the registry records.
NCT06799247 · Cartesian Therapeutics
Before: Estimated. After: Actual.
Before: 100 participants (planned). After: 128 participants (actual).
Before: 30 Nov 2026. After: 30 Dec 2026.
Before: Recruiting. After: Active not recruiting.
NCT04146051 · Cartesian Therapeutics
Before: Estimated. After: Actual.
Before: 31 Jul 2025. After: 5 Jan 2026.
NCT07391605 · Cartesian Therapeutics
Before: Nov 2026. After: Nov 2027.
Before: Not yet recruiting. After: Recruiting.
NCT06038474 · Cartesian Therapeutics
Before: 1 Dec 2025. After: 1 Dec 2026.
NCT06038474 · Cartesian Therapeutics
Before: Estimated. After: Actual.
Before: 30 participants (planned). After: 6 participants (actual).
Before: 1 Nov 2025. After: 1 Dec 2025.
Before: Recruiting. After: Active not recruiting.